Related Experiment Videos
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
1Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.
Therapeutic Drug Monitoring
|April 1, 1992
Summary
Genetic factors significantly impact haloperidol metabolism. Poor metabolizers of debrisoquine exhibit slower haloperidol elimination, increasing the risk of adverse effects at standard doses.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Clinical Pharmacology
Background:
- Genetic variations influence drug metabolism.
- Debrisoquine hydroxylation is a well-established pharmacogenetic marker.
- Haloperidol is an antipsychotic medication with variable patient response.
Purpose of the Study:
- To determine the role of genetic factors in haloperidol metabolism.
- To investigate the association between debrisoquine metabolizer status and haloperidol disposition.
- To assess the clinical implications for haloperidol dosing.
Main Methods:
- Studied haloperidol pharmacokinetics in extensive (EM) and poor (PM) debrisoquine metabolizers.
- Administered a single oral dose of haloperidol.
- Monitored plasma concentrations and calculated elimination half-life and clearance.
Main Results:
- Poor metabolizers (PM) showed significantly slower haloperidol elimination compared to extensive metabolizers (EM).
- PM had a longer plasma half-life (29.4 vs. 16.3 h) and lower clearance (1.16 vs. 2.49 L/h/kg).
- PM experienced side effects at standard doses, necessitating dose reduction.
Conclusions:
- Haloperidol disposition is linked to the genetic capacity for debrisoquine hydroxylation.
- Poor debrisoquine metabolizers may face increased haloperidol side effect risk due to higher plasma concentrations.
- Rapid metabolizers might require higher haloperidol doses for therapeutic efficacy.